1 February 2016 in International Immunopharmacology
1 June 2016 in The Egyptian Journal of Internal Medicine
Introduction Atherosclerotic coronary artery disease is considered to be the most common cause of myocardial ischemia. YKL-40, a chitin-binding acute phase glycoprotein, has been found to be expressed by macrophages in atherosclerotic plaques. The YKL-40 could potentially be a new useful biomarker to monitor severity and predict early diagnosis of acute coronary syndrome (ACS) in ischemic heart disease (IHD) patients. Aim The aim of this study was to measure the level of serum YKL-40 in IHD patients and to clarify its role as a potentially beneficial diagnostic marker in those patients. Patients and methods Serum YKL-40 was measured in 60 IHD patients and 30 healthy controls. According to chest pain analysis, ECG changes, and cardiac enzymes, the IHD patients were categorized into patients with stable angina and patients with ACS. Results The median level of YKL-40 (pg/ml) was significantly elevated in patients with IHD compared with the control group (2080 (575.5–5974.6) vs 522.6 (133.2–769.5), respectively; P<0.001). The median level of YKL-40 was also significantly higher in patients with ACS compared with patients with stable angina (2436 (576–5975) vs 1015 (675–1822), respectively; P˂0.001). There was a positive correlation between YKL-40 levels and high-sensitivity C-reactive protein (mg/dl) in all studied groups of IHD patients. However, no significant correlation was detected between YKL-40 and age, systolic or diastolic blood pressure, and lipid profile in patients with IHD. Conclusion YKL-40 might play an important role as a diagnostic and prognostic marker in patients with IHD and in patients with ACS.
1 December 2019 in Journal of the Egyptian Society of Parasitology
Non-alcoholic steatohepatitis (NASH) is a worldwide health problem and imposes a high cost on healthcare system, and NASH is associated with an unhealthy lifestyle. This study investigated whether low carbohydrate diet intervention physical activity and affect intrahepatic fat content and hepatic enzymes. The current interventional study included participants who were over 18 years with NASH (n= 30) with BMI over 25 kg/m2. The effects of proper nutritional therapy (moderate caloric restriction, low carbohydrate) was tested through personal dietary and physical assessment,parameters of the metabolic syndrome and insulin resistance in addition to liver biochemical and imaging study . The assessment was done at baseline and at 3 months by the same observer. The results showed that after 3 months of intervention, patients had a significant decrease in caloric consumption, weight loss (p < 0.001) and HOMA-IR had significant improvements. Lipid profile after 3 months showed significant reduction including cholesterol and triglycerideslevels (p < 0.05). Regarding liver profile significant decrease observed in aminotransferases levels; also there were significant improvements in AST/ALT ratio with decrease in severity of liver steatosis.
1 December 2019 in Journal of the Egyptian Society of Parasitology
The incidence of acute and chronic rejection has declined with improvement of immunosuppression regimens in liver transplant recipients. The CD44 protein belongs to a large family of type I Trans membrane glycoproteins and expressed on the surface of most vertebrate cells and is an important receptor for the components of extracellular matrix. The study evaluated if the serum level of CD44 had a value in diagnosis of acute rejection depending on proved rejection by liver biopsy. The patients were recruited from ASCOT from May 2017 to December 2018. They were 20 adults with Post LDLT with elevated liver function tests and were reviewed. The results showed that serum level of CD44 was significantly lower in the rejection group in our study in patient with post liver transplantation. There was highly significant difference between controls & patients as regards serum level of CD44. Negative correlation between serum levels of CD44, WBCs & AST. There was highly significant difference between patients with different pathological findings as regards serum level of CD44. The best cut off point for serum level of CD44 as a marker of rejection was found ≤ 44ng/ml with sensitivity of 85% and specificity of 95% in diagnosis of acute cellular rejection.